About ReNeuron Group
ReNeuron Group is a company based in Guildford (United Kingdom) founded in 1997. The company has 34 employees. ReNeuron Group offers products and services including Engineered Exosomes. ReNeuron Group operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Guildford, United Kingdom
- Employees 34
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website reneuron.com
- Social LinkedIn
- Legal Name Reneuron Group Plc.
- Annual Revenue$653.65 K (USD)23.5as on Mar 31, 2023
- Net Profit-$6.67 M (USD)47.58as on Mar 31, 2023
- EBITDA-$8.45 M (USD)41.01as on Mar 31, 2023
- Latest Funding Round$2.14M (USD), Grant
Apr 2018
- InvestorsGov.uk
& 1 more
- Employee Count34
Products & Services of ReNeuron Group
ReNeuron Group offers a comprehensive portfolio of products and services, including Engineered Exosomes.
Stem cell-based technologies for targeting tissues and delivering specific payloads.
Funding Insights of ReNeuron Group
- Total Rounds 7
- Last Round Grant — $2.14M
- First Round $78,142
(Feb 2010)
- Investors Count 2
All 7 funding rounds of ReNeuron Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $2.14M | Grant | – | – | |
| May 2017 | $2.33M | Grant | – | – | |
| Aug 2015 | $106.11M | Post-IPO | – | – | – |
| Jul 2015 | $105.15M | Post-IPO | – | – | – |
| Jul 2013 | $28.5M | Post-IPO | – | – | – |
| Feb 2010 | $82M | Post-IPO | – | – | – |
| Feb 2010 | $78,142 | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in ReNeuron Group
ReNeuron Group has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gov.uk and Seneca Growth Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Assets are managed for growth-oriented investments in the UK. | 2001 | senecavct.co.uk | Haydock, United Kingdom |
Investor details for ReNeuron Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReNeuron Group
8 people are tracked at ReNeuron Group (7 in board & advisors, 1 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Martin Walton | Non-Executive Director | Board & advisors |
José-Alain Sahel | Advisor | Board & advisors |
Giuseppe Battaglia | Advisor | Board & advisors |
Bernd Giebel | Advisor | Board & advisors |
Kenneth W. Witwer | Advisor | Board & advisors |
Barbara Staehelin | Senior Independent Non-Executive Director | Board & advisors |
Stefano Pluchino | Chair of the Scientific Advisory Board | Board & advisors |
Iain Ross | Executive Chairman | Team |
Complete people profiles for ReNeuron Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ReNeuron Group
ReNeuron Group is a publicly listed company on the OTC with ticker symbol RNUGF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Aug 2005
- Listed onLSE: RENE
- Listed entityReneuron Group Plc.
- Exchange sectorHealth technology
- ISINGB00BF5G6K95
- Share price$0.00 · 2026-05-11
- Volume (last session)3,018
- Analyst consensusNo rating
Financials of ReNeuron Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $653,650 | -$6.7M | -$8.4M |
| 2021 | $529,260 | -$12.7M | -$14.3M |
| 2020 | $354,580 | -$15.7M | -$17.4M |
Detailed financial statements for ReNeuron Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ReNeuron Group
4 dated milestones of ReNeuron Group across 21 years, from founding to its latest funding, stage changes and deals.
- Founded ReNeuron Group is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $78K.
- Funding Latest funding round, Grant, of $2.1M.
Competitors of ReNeuron Group
ReNeuron Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of ReNeuron Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReNeuron Group
The website of ReNeuron Group (reneuron.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 31.6% vs previous month
Websites whose visitors overlap most with ReNeuron Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| beikebiotech.com | 100% | – | #8,745,362 | View details | |
san-bio.com | san-bio.com | 99% | – | – | – |
| apceth.com | 98% | – | – | View details |
Latest news on Reneuron Group
Complete news archive for ReNeuron Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ReNeuron Group
10 companies that operate in the same segment as ReNeuron Group (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ReNeuron Group
ReNeuron Group was founded in 1997 and raised its 1st funding round 13 years after it was founded.
ReNeuron Group is headquartered in Guildford, United Kingdom.
ReNeuron Group has 34 employees.
Annual revenue of ReNeuron Group is $653.65K as on Mar 31, 2023.
ReNeuron Group was founded in 1997 in Guildford, United Kingdom, within the biotechnology sector. Stem-cell-based therapeutics are developed by the company for treating stroke disability and critical limb ischemia. The product pipeline features ReN001 for disabled stroke patients, along with human retinal progenitor cell therapy for retinitis pigmentosa and CTX cells for Parkinsons disease and ischemic stroke. Operations center on advancing these regenerative medicine solutions.
ReNeuron Group's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
ReNeuron Group offers Engineered Exosomes.
Yes, ReNeuron Group is publicly traded on OTC under the ticker symbol RNUGF.
ReNeuron Group has 2 investors. Key investors include Gov.uk, and Seneca Growth Capital.
ReNeuron Group operates through Reneuron Group Plc.